Background

NAD+ precursors (NMN/NR) reliably raise circulating NAD+ but show limited impact on composite biological age clocks in humans {1}. Rapamycin administered intermittently (weekly 2‑10 mg) inhibits mTORC1 while sparing mTORC2, improves autophagy and has promising longevity signals in rodents and humans {5}. However, whether rapamycin can potentiate the epigenetic effects of NAD+ boosting remains unexplored.

Hypothesis

Weekly low‑dose rapamycin will synergize with daily NMN supplementation to produce a greater reduction in epigenetic age (e.g., GrimAge) than either intervention alone, by enhancing NAD+-dependent SIRT1 activity through mTORC1‑mediated de‑repression of the NAD+ salvage pathway.

Mechanistic Reasoning

• mTORC1 activation suppresses NAMPT transcription via HIF‑1α‑dependent pathways, limiting NAD+ synthesis. Rapamycin‑induced mTORC1 inhibition lifts this brake, increasing NAMPT expression and intracellular NAD+ pools beyond what precursors alone provide.
• Higher NAD+ fuels SIRT1 deacetylase activity, which in turn deacetylates and activates PGC‑1α and FOXO3, promoting mitochondrial biogenesis and stress resistance—processes linked to slower epigenetic aging.
• Rapamycin also stimulates autophagy, clearing damaged mitochondria and reducing NAD+‑consuming PARP activation, further preserving NAD+ for sirtuin signaling.
• The combined effect yields a feed‑forward loop: more NAD+ → more SIRT1 → better mitochondrial health → less NAD+ consumption, amplifying the age‑reverting signal.

Testable Predictions

1. Participants receiving rapamycin + NMN will show a statistically significant greater decrease in GrimAge (or another validated epigenetic clock) after 12 weeks compared to rapamycin alone, NMN alone, and placebo.
2. The combined group will exhibit higher whole‑blood NAD+ levels and increased SIRT1 target deacetylation (e.g., acetylated PGC‑1α) than the additive sum of the monotherapies.
3. Improvements in epigenetic age will correlate with changes in autophagy markers (LC3‑II/I ratio) and NAMPT expression in peripheral blood mononuclear cells.

Experimental Design (Falsifiable)

• Design: Randomized, double‑blind, 4‑arm crossover trial in 80 healthy adults aged 45‑65, each arm lasting 12 weeks with a 4‑week washout.
• Arms: (1) Placebo, (2) NMN 500 mg daily, (3) Rapamycin 3 mg weekly (Monday), (4) NMN + rapamycin (same doses).
• Primary Outcome: Change in GrimAge from baseline to week 12.
• Secondary Outcomes: Serum NAD+, PBMC NAMPT mRNA, SIRT1 activity (deacetylation of PGC‑1α), autophagy flux (LC3‑II/I, p62), standard clinical safety labs.
• Statistical Plan: ANOVA with post‑hoc Tukey; synergy defined as the combination effect exceeding the sum of individual effects by >15 % (interaction term p < 0.05).

Potential Outcomes and Falsifiability

• If the combination yields a greater GrimAge reduction than additive, the hypothesis is supported, indicating that mTORC1 inhibition enhances NAD+ precursor efficacy via SIRT1‑mediated pathways.
• If the combination shows no additional benefit beyond the sum of monotherapies (or shows antagonism), the hypothesis is falsified, suggesting that rapamycin does not meaningfully augment NAD+‑driven epigenetic remodeling in humans.

Conclusion

This hypothesis links two prominent longevity interventions through a concrete molecular circuit—mTORC1‑NAMPT‑NAD+‑SIRT1—offering a clear, falsifiable roadmap for next‑generation self‑experimentation and clinical trials.